US Bancorp DE Reduces Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

US Bancorp DE reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 46.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 945 shares of the company’s stock after selling 818 shares during the period. US Bancorp DE’s holdings in Krystal Biotech were worth $172,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. EFG Asset Management North America Corp. raised its holdings in Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after buying an additional 60 shares during the period. GAMMA Investing LLC raised its stake in shares of Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after acquiring an additional 93 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Krystal Biotech by 11.1% in the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after acquiring an additional 94 shares during the period. Arizona State Retirement System lifted its holdings in shares of Krystal Biotech by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after acquiring an additional 108 shares during the last quarter. Finally, Fiera Capital Corp boosted its stake in shares of Krystal Biotech by 0.8% during the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after purchasing an additional 130 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Trading Down 3.7 %

KRYS opened at $177.39 on Friday. The business’s fifty day simple moving average is $181.27 and its 200-day simple moving average is $181.38. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of 104.08 and a beta of 0.82. Krystal Biotech, Inc. has a 12-month low of $96.73 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. During the same period in the prior year, the business earned ($0.67) EPS. The firm’s quarterly revenue was up 879.9% on a year-over-year basis. On average, equities research analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of recent analyst reports. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Stifel Nicolaus raised their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Chardan Capital upped their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Citigroup lifted their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $197.00.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).